Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas.

Abstract

Uterine sarcomas are rare, high-risk malignancies. Expert histologic review is important for accurate diagnosis. For high-grade leiomyosarcomas, the risk of recurrence is high after complete resection of uterus-limited disease; however, no adjuvant therapy has been proven to improve survival. Chemotherapy regimens with efficacy in treating advanced uterine leiomyosarcoma include gemcitabine-docetaxel, doxorubicin and ifosfamide. Uterine carcinosarcomas also carry a high risk of recurrence. Adjuvant chemotherapy is a standard approach for completely resected and metastatic carcinosarcoma. Active agents include carboplatin, cisplatin, ifosfamide and paclitaxel.

• Authors: Martee L Hensley
• Journal: Best practice & research. Clinical obstetrics & gynaecology (Best Pract Res Clin Obstet Gynaecol) Vol. 25 Issue 6 Pg. 773-82 (Dec 2011) ISSN: 1532-1932 [Electronic] Netherlands
• PMID: 21752717 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols
• Carcinosarcoma (drug therapy, surgery)
• Chemotherapy, Adjuvant
• Female
• Humans
• Leiomyosarcoma (drug therapy, surgery)
• Sarcoma (drug therapy, surgery)
• Uterine Neoplasms (drug therapy, surgery)